US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(OP:
SDZNY
)
82.86
+0.28 (+0.34%)
Delayed Quote
Updated: 3:50 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SDZNY
< Previous
1
2
Next >
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
↗
September 11, 2024
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.
Via
Benzinga
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
August 12, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports second-quarter sales and half-year 2024 results
August 08, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
July 25, 2024
From
Sandoz Group
Via
GlobeNewswire
3 Spinoff Stocks You Should Buy Now: July 2024
↗
July 15, 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early.
Via
InvestorPlace
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Upcoming Stock Spinoffs: Should You Pounce or Pass?
↗
July 04, 2024
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.
Via
InvestorPlace
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports first quarter 2024 sales
May 07, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
↗
April 30, 2024
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
Via
Benzinga
Topics
Intellectual Property
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
March 13, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives FDA approval for first and only denosumab biosimilars
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz announces nominations to the Board of Directors and leadership change
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
March 04, 2024
From
Sandoz Group
Via
GlobeNewswire
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
↗
February 29, 2024
Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with...
Via
Benzinga
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
February 29, 2024
From
Sandoz Group
Via
GlobeNewswire
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
↗
January 22, 2024
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.
Via
Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
↗
December 04, 2023
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:
Via
Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
↗
October 24, 2023
Novartis AG (NYSE: NVS) reported
Via
Benzinga
Topics
Earnings
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
October 09, 2023
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.
Via
MarketBeat
< Previous
1
2
Next >
